Success Metrics

Clinical Success Rate
88.8%

Based on 111 completed trials

Completion Rate
89%(111/125)
Active Trials
23(13%)
Results Posted
34%(38 trials)
Terminated
14(8%)

Phase Distribution

Ph early_phase_1
11
6%
Ph not_applicable
32
17%
Ph phase_2
31
17%
Ph phase_3
19
10%
Ph phase_4
54
30%
Ph phase_1
23
13%

Phase Distribution

34

Early Stage

31

Mid Stage

73

Late Stage

Phase Distribution170 total trials
Early Phase 1First-in-human
11(6.5%)
Phase 1Safety & dosage
23(13.5%)
Phase 2Efficacy & side effects
31(18.2%)
Phase 3Large-scale testing
19(11.2%)
Phase 4Post-market surveillance
54(31.8%)
N/ANon-phased studies
32(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.0%

111 of 129 finished

Non-Completion Rate

14.0%

18 ended early

Currently Active

23

trials recruiting

Total Trials

183

all time

Status Distribution
Active(28)
Completed(111)
Terminated(18)
Other(26)

Detailed Status

Completed111
unknown26
Recruiting18
Terminated14
Active, not recruiting5
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
183
Active
23
Success Rate
88.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (6.5%)
Phase 123 (13.5%)
Phase 231 (18.2%)
Phase 319 (11.2%)
Phase 454 (31.8%)
N/A32 (18.8%)

Trials by Status

unknown2614%
terminated148%
not_yet_recruiting42%
recruiting1810%
withdrawn42%
active_not_recruiting53%
completed11161%
enrolling_by_invitation11%

Recent Activity

Clinical Trials (183)

Showing 20 of 183 trialsScroll for more
NCT03575403Phase 1

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

Completed
NCT05630781Not Applicable

Orexin s Role in the Neurobiology of Substance Use Disorder

Recruiting
NCT05285683Phase 2

The Role of Brain Dopamine in Chronic Pain

Recruiting
NCT04421248Phase 4

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Recruiting
NCT00914095Phase 4

Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)

Completed
NCT01821170Not Applicable

Cognitive Remediation in ADHD Children : Comparison Between Three Therapeutic Strategies : Cognitive Remediation With a Virtual Classroom Software and Methylphenidate and Supportive Psychotherapy

Completed
NCT07314333Phase 1

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

Completed
NCT03772834Phase 2

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

Active Not Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT04419272Phase 4

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

Recruiting
NCT03525873Phase 3

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

Active Not Recruiting
NCT05561205Not Applicable

rTMS for Apathy Clinical Trial

Recruiting
NCT01410942Phase 2

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Active Not Recruiting
NCT07301632Phase 2

Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial

Recruiting
NCT03652740Phase 1

Effects of Commonly Used Medications on Mood and Choice

Completed
NCT05776056Phase 4

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

Recruiting
NCT02879136Early Phase 1

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

Completed
NCT03280251Phase 2

Methylphenidate and Cognitive Training in Elderly

Completed
NCT06081179Phase 1

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans

Completed
NCT05474846Phase 2

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
183